B. Riley restated their buy rating on shares of GENFIT S A/ADR (NASDAQ:GNFT) in a research note issued to investors on Friday, Stock Target Advisor reports. They currently have a $43.00 price objective on the stock.
A number of other research firms also recently weighed in on GNFT. Svb Leerink reiterated an outperform rating on shares of GENFIT S A/ADR in a research note on Thursday, January 2nd. HC Wainwright decreased their price target on shares of GENFIT S A/ADR from $72.00 to $58.00 and set a buy rating on the stock in a research note on Thursday, October 31st. Finally, Zacks Investment Research downgraded shares of GENFIT S A/ADR from a buy rating to a hold rating in a research note on Monday, January 27th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $43.75.
GNFT opened at $16.85 on Friday. GENFIT S A/ADR has a fifty-two week low of $13.21 and a fifty-two week high of $26.25. The company has a current ratio of 6.45, a quick ratio of 6.44 and a debt-to-equity ratio of 1.85. The firm’s fifty day moving average price is $18.72 and its two-hundred day moving average price is $16.87.
Institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE acquired a new stake in GENFIT S A/ADR during the fourth quarter worth $26,000. Morgan Stanley boosted its stake in GENFIT S A/ADR by 24.4% during the second quarter. Morgan Stanley now owns 10,700 shares of the company’s stock worth $211,000 after buying an additional 2,100 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of GENFIT S A/ADR in the 4th quarter valued at $454,000. Bank of America Corp DE acquired a new stake in shares of GENFIT S A/ADR in the 2nd quarter valued at $889,000. Finally, Millennium Management LLC boosted its stake in shares of GENFIT S A/ADR by 51.4% in the 3rd quarter. Millennium Management LLC now owns 128,001 shares of the company’s stock valued at $2,228,000 after purchasing an additional 43,464 shares in the last quarter. Hedge funds and other institutional investors own 2.17% of the company’s stock.
GENFIT S A/ADR Company Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Featured Article: How Do I Invest in Dividend Stocks
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.